GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atea Pharmaceuticals Inc (NAS:AVIR) » Definitions » Price-to-Tangible-Book

Atea Pharmaceuticals (Atea Pharmaceuticals) Price-to-Tangible-Book : 0.56 (As of Apr. 30, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Atea Pharmaceuticals Price-to-Tangible-Book?

As of today (2024-04-30), Atea Pharmaceuticals's share price is $3.71. Atea Pharmaceuticals's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $6.65. Hence, Atea Pharmaceuticals's Price to Tangible Book Ratio of today is 0.56.

The historical rank and industry rank for Atea Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

AVIR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.46   Med: 0.84   Max: 6.29
Current: 0.56

During the past 6 years, Atea Pharmaceuticals's highest Price to Tangible Book Ratio was 6.29. The lowest was 0.46. And the median was 0.84.

AVIR's Price-to-Tangible-Book is ranked better than
92.87% of 1220 companies
in the Biotechnology industry
Industry Median: 2.69 vs AVIR: 0.56

A closely related ratio is called PB Ratio. As of today, Atea Pharmaceuticals's share price is $3.71. Atea Pharmaceuticals's Book Value per Sharefor the quarter that ended in Dec. 2023 was $6.65. Hence, Atea Pharmaceuticals's P/B Ratio of today is 0.56.


Atea Pharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for Atea Pharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atea Pharmaceuticals Price-to-Tangible-Book Chart

Atea Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial - 6.29 1.05 0.63 0.46

Atea Pharmaceuticals Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.63 0.45 0.52 0.43 0.46

Competitive Comparison of Atea Pharmaceuticals's Price-to-Tangible-Book

For the Biotechnology subindustry, Atea Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atea Pharmaceuticals's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atea Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Atea Pharmaceuticals's Price-to-Tangible-Book falls into.



Atea Pharmaceuticals Price-to-Tangible-Book Calculation

Atea Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=3.71/6.654
=0.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Atea Pharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Atea Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Atea Pharmaceuticals (Atea Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
225 Franklin Street, Suite 2100, Boston, MA, USA, 02110
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
Executives
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Polly A. Murphy director C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Jerome M. Adams director C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Cormorant Global Healthcare Master Fund, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Hack Andrew A. F. director 300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Rock Springs Capital Master Fund Lp 10 percent owner 190 ELGIN AVENUE, GEORGE TOWN E9 KY1 9001
Jean-pierre Sommadossi director, 10 percent owner, officer: President, CEO, and Chairman 125 SUMMER STREET, 16TH FLOOR, BOSTON MA 02110
Jpm Partners Llc 10 percent owner C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Chung K. Chu 10 percent owner C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Janet Mj Hammond officer: Chief Development Officer C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Isaac Cheng director C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
John Vavricka officer: Chief Commercial Officer C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Bruno Lucidi director C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Maria Arantxa Horga officer: Acting Chief Medical Officer C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Bruce Polsky director C/O VISION-SCIENCES, INC., 40 RAMLAND ROAD, ORANGEBURG NY 10962

Atea Pharmaceuticals (Atea Pharmaceuticals) Headlines

From GuruFocus